Aricept (Donepezil HCl) Patent Expiration, LOE Window & CMS Spending
Aricept (Donepezil HCl) by Eisai: FDA Orange Book LOE 2026-10-04, 20 AB generics, $1.2M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Eisai |
| FDA Application & Pathway | N020690 (NDA) |
| Exclusivity / Cliff Horizon | Immediate Cliff (2025-2027) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2026-10-04 |
| Orange Book Patents (*PED Extensions) | 1 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 20 |
| 2024 CMS Total Public Spend | $1.2M |
| 2024 Medicare Part D Spend | $1.2M |
| 2024 Medicaid Spend | $59K |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Eisai across sibling Meru public-data platforms.